46,486 Shares in Abivax SA Sponsored ADR $ABVX Bought by TD Asset Management Inc

TD Asset Management Inc bought a new stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 46,486 shares of the company’s stock, valued at approximately $3,947,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in ABVX. Bank of America Corp DE boosted its stake in shares of Abivax by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after acquiring an additional 1,990 shares in the last quarter. Cubist Systematic Strategies LLC boosted its position in Abivax by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after purchasing an additional 2,595 shares during the period. Millennium Management LLC grew its holdings in Abivax by 6.0% during the first quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock valued at $6,171,000 after purchasing an additional 56,235 shares during the last quarter. Woodline Partners LP grew its holdings in Abivax by 319.5% during the first quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock valued at $1,262,000 after purchasing an additional 153,788 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Abivax in the second quarter valued at approximately $139,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Stock Down 1.8%

Shares of ABVX opened at $111.10 on Wednesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. The company has a 50-day simple moving average of $123.24 and a 200-day simple moving average of $106.92. Abivax SA Sponsored ADR has a 52 week low of $4.77 and a 52 week high of $148.83. The firm has a market capitalization of $8.78 billion, a P/E ratio of -26.58 and a beta of 1.00.

Abivax (NASDAQ:ABVX) last released its quarterly earnings data on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The firm had revenue of ($4.92) million for the quarter. On average, equities research analysts expect that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ABVX shares. Truist Financial set a $140.00 target price on shares of Abivax in a research note on Monday, November 24th. Citigroup restated a “market outperform” rating on shares of Abivax in a report on Thursday, January 8th. Wedbush started coverage on Abivax in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $110.00 price target on the stock. Piper Sandler reissued an “overweight” rating and set a $142.00 price objective on shares of Abivax in a research report on Tuesday, December 16th. Finally, Citizens Jmp increased their target price on Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research note on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.75.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.